Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

123
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
123
Hazard Ratio01:12

Hazard Ratio

91
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
91

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Singular Value Decomposition-Based Coil Combination Improves the Accuracy and Noise-Robustness of Quantitative Susceptibility Maps.

medRxiv : the preprint server for health sciences·2026
Same author

Clinical and biochemical characterization of amyotrophic lateral sclerosis in a CHCHD10 R15L family.

Brain : a journal of neurology·2026
Same author

Assessing verbal and spatial memory via smartphone.

Frontiers in digital health·2026
Same author

Extrapolating from trials to clinic: a predictive model defining the boundaries of benefit for multiple sclerosis therapies in real-world populations based on systematic review.

BMC medicine·2026
Same author

Utilization of a Deep Learning Algorithm for Automated Segmentation of Median Nerve from Ultrasound Obtained from the Distal Forearm and Wrist.

Bioengineering (Basel, Switzerland)·2025
Same author

Distinct medial temporal volumetric signatures in extra-medial temporal lobe lesional epilepsy.

Epilepsia open·2025
Same journal

Predicting Chemotherapy Response from Staging Laparoscopy Images.

medRxiv : the preprint server for health sciences·2026
Same journal

Development and External Validation of a Machine Learning Model for 10-Year Ischemic Stroke Risk Prediction in Diverse Populations.

medRxiv : the preprint server for health sciences·2026
Same journal

MCH-Guard: Multimodal Machine Learning Framework for Risk Stratification of Cerebral Microhemorrhage Risk in the Alzheimer's Disease Neuroimaging Initiative.

medRxiv : the preprint server for health sciences·2026
Same journal

Genetic and maternal environmental contributions to estimated fetal weight at 20 weeks gestation compared with birthweight.

medRxiv : the preprint server for health sciences·2026
Same journal

Better immediate declarative memory is associated with forgetting during locomotor adaptation in chronic stroke and in older adults.

medRxiv : the preprint server for health sciences·2026
Same journal

An empirical Bayes framework for burden and dispersion association tests helps prioritize rare variants associated with Alzheimer's disease.

medRxiv : the preprint server for health sciences·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K

Data-driven risk/benefit estimator for multiple sclerosis therapies.

Bibiana Bielekova1, Tianxia Wu2, Peter Kosa1

  • 1Neuroimmunological Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Medrxiv : the Preprint Server for Health Sciences
|October 7, 2024
PubMed
Summary
This summary is machine-generated.

Individualized risk-benefit analysis for multiple sclerosis (MS) disease-modifying treatments (DMTs) is crucial. Current DMTs may cause more harm than benefit in patients not selected for clinical trials, highlighting the need for personalized treatment strategies.

More Related Videos

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.9K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.5K

Related Experiment Videos

Last Updated: Jun 11, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

57.9K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.5K

Area of Science:

  • Neurology
  • Clinical Pharmacology
  • Biostatistics

Background:

  • Disease-modifying treatments (DMTs) for multiple sclerosis (MS) are typically evaluated in preselected patient cohorts.
  • Broad prescription of DMTs in clinical practice necessitates understanding individualized risk-benefit profiles.

Purpose of the Study:

  • To develop data-driven computations for individualized risk-benefit ratios of MS DMTs.
  • To optimize multiple sclerosis care through personalized risk-benefit assessments.

Main Methods:

  • Re-analysis and integration of 61 Phase 2b/3 randomized controlled trials (46,611 patients, 91,787 patient-years).
  • Extraction and computation of patient features to identify and adjust for biases in regression models.
  • Estimation of DMTs mortality risks using age-adjusted mortality tables and hazard ratios.

Main Results:

  • Patient baseline characteristics significantly influence disability progression and DMT efficacy.
  • DMT efficacy is positively correlated with MS lesional activity and negatively with age, disease duration, and disability.
  • DMT efficacy diminishes rapidly with treatment duration, while risks increase with age, disability, and comorbidities.

Conclusions:

  • Prescribing DMTs to patients outside of clinical trial criteria may lead to more harm than benefit.
  • Optimizing MS care involves initiating high-efficacy treatments at onset and de-escalating to DMTs with lower infectious risks.
  • Development of novel DMTs targeting progression mechanisms independent of lesional activity is essential.